Axcelis Technologies (ACLS)
Builds ion implanters and lifecycle services for silicon and silicon-carbide chip production.
Something off on this page? Send us feedback.
Sells Purion and Ovation ion implanters to semiconductor fabs and earns aftermarket revenue from parts, upgrades, used tools, maintenance, and training. Power-device applications account for most recent annual system shipments by value, while sales depend on chipmakers' capital spending and U.S. export controls affecting China.
Builds and services ion-implantation equipment used to place dopants into silicon and silicon-carbide wafers during chip fabrication. The Purion family spans high-current, high-energy, and medium-current systems; its Power Series targets power-device production, while Ovation serves batch implantation. Customer Solutions & Innovation supplies used tools, parts, upgrades, maintenance, and training across the installed base.
Pairs a common-platform product architecture with in-house system assembly and testing, while sourcing non-core modules from global partners. Power-device applications represented most of the latest annual system shipment value. Most sales are international, and China has been a significant market, tying shipments to U.S. export controls. An all-stock merger with Veeco remains pending final regulatory approval in China.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 7, 2026 | Craig-Hallum | Downgrade | Target: $174 | Target: $140 |
| Apr 20, 2026 | B. Riley Securities | Upgrade | ||
| Oct 13, 2025 | B of A Securities | Downgrade | ||
| Oct 2, 2025 | DA Davidson | Reiterate | Rating: —Target: $75 | Target: $110 |
| Oct 2, 2025 | Benchmark | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $402.2M · Total debt $41.6M · Total assets $1.39B · Shareholders' equity $1.07B
- Revenue
- $215.2M
- Operating income
- $20.3M
- Net income
- $23.3M
No dividends on record.
| Institutions | ≈ 102.13% | 31.39M shares | |
|---|---|---|---|
| 459 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.49% | 457.1K shares | |
| 17 holders · as of Sep 16, 2026 | |||
| Adds to | 103.62% | ||
30.73M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 103.62%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 16.36% | 5.03M | as of Jun 30, 2026 |
FMR LLCInstitution | 13.42% | 4.13M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 8.07% | 2.48M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.51% | 1.39M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.01% | 1.23M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 3, 2026 | Necip Sayiner | director | −1,586 | $157.44 |
| May 27, 2026 | Todd Sutton | officer: VP Corporate Controller | −2,000 | $159.99 |
| May 22, 2026 | Thomas st Dennis | director | −900 | $155.37 |
| May 21, 2026 | Gerald M. Blumenstock | officer: EVP, Research, Dev. & Eng. | −1,161 | $152.70 |
| May 22, 2026 | Eileen Evans | officer: EVP, General Counsel and Sec'y | −926 | $155.51 |
- Applied Materials
Only other full-range ion implant vendor; Varian-heritage platform, ~60% share.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Axcelis Technologies | $113.81 | +0.58% | $3.48B | 38.0 | 23.5 | 4.0 | +10.6% |
| Applied Materials | $466.25 | +0.43% | $368.59B | 40.0 | 26.5 | 12.0 | +24.8% |
| Median | 40.0 | 26.5 | 12.0 | +24.8% |